




Supporting Information Fig 1. Pharmacokinetic and potency characterization of MT 63-78.

A. Pharmacokinetic of MT 63-78. MT 63-78 was administered in three mice i.p. or orally using Mylanta as vehicle. In the left panel, 10 mg/kg of MT 63-78 were administered i.p. or orally in C57BL/6 mice. Each data point represents the pooled plasma collected from the three mice at the different time points and analyzed by LC/MS/MS. In the right panel, 2 mg/kg of MT 63-78 were administered i.p. or orally in C57BL/6 mice. Plasma was collected at each time point and analyzed separately. Results are expressed as mean $\pm$ SD. Oral bioavailability was calculated as the ratio AUC (oral dose)/AUC (i.p. dose) as described in Supporting Materials and Methods.

B. AMPK activity in LNCaP and PC3 cells measured with Alpha Screen Assay, as described in Supporting Materials and Methods. Assay was performed in cell lysates following 30-min treatment with MT 63-78, A-769662 (100uM), and AICAR (2mM). Results are expressed as means $\pm$ SD of three independent samples. One-way ANOVA test, followed by Tukey's post hoc test for multiple comparisons was performed and significant p values are reported on the bar graphs. Cps= count per second.